Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Commodities

Piedmont Lithium Stock Ceases Trading Following Merger Completion

Robert Sasse by Robert Sasse
September 30, 2025
in Commodities, Mergers & Acquisitions, Penny Stocks
0
Piedmont Lithium Stock
0
SHARES
100
VIEWS
Share on FacebookShare on Twitter

The final chapter has closed for Piedmont Lithium as a publicly traded entity. Following the formal consolidation with Sayona Mining on August 29, 2025, the lithium company’s shares were officially delisted from all exchanges. Trading under the ticker PLL concluded permanently, with the security declared worthless effective September 1, 2025, and subsequently removed from the ASX on September 10.

Shareholder Transition to New Entity

Investors holding Piedmont Lithium stock received 0.35133 American Depositary Shares of the newly formed Elevra Lithium (Nasdaq: ELVR) in exchange for each of their previous holdings. These ADS units represent 527 ordinary shares of the combined company. This conversion process effectively transferred all ownership interests to the merged entity. Leadership of the new organization falls to Lucas Dow, formerly of Sayona Mining, who now serves as President and Chief Executive Officer of Elevra Lithium.

Financial Performance Preceded Consolidation

The merger materialized after Piedmont Lithium disclosed disappointing quarterly results. For the second quarter of 2025, the company reported a per-share loss of $0.44, falling substantially short of analyst projections. Conversely, revenue figures surprised positively, with $11.86 million in sales exceeding market expectations. Regulatory clearances for the transaction had been secured since April 2025, paving the way for the eventual combination.

Should investors sell immediately? Or is it worth buying Piedmont Lithium?

Strategic Positioning of Combined Company

This corporate union establishes one of the globe’s most significant hard-rock lithium platforms. Elevra Lithium now occupies a strategic position within the expanding electric vehicle battery supply chain. The newly consolidated enterprise has outlined several key operational priorities:

  • Implementation of measured growth initiatives
  • Enhanced financial structuring for project development
  • Updated JORC resource estimates for both NAL and Moblan assets

Market participants now monitor the progress of this emerging lithium producer under the fresh ticker ELVR, marking the definitive conclusion of the Piedmont Lithium investment story.

Ad

Piedmont Lithium Stock: Buy or Sell?! New Piedmont Lithium Analysis from February 8 delivers the answer:

The latest Piedmont Lithium figures speak for themselves: Urgent action needed for Piedmont Lithium investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Piedmont Lithium: Buy or sell? Read more here...

Tags: Piedmont Lithium
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Varonis Stock

Varonis Stock Positioned for Growth Amid AI and Cloud Expansion

SentinelOne Stock

Can SentinelOne's AI Bet Reverse Its Fortunes?

Blackrock TCP Capital Stock

High-Yield Trap: Blackrock TCP Capital Shares Plummet Despite Dividend Payout

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com